Product Design, Manufacturing & Innovation Resources

Latest Publications & Patents on Molecular Oncology

Molecular Oncology Publications Patents

Tip: further to the selection below, you can search and filter our 2 entire databases:

> free publications search tool < by author, topic, keywords, date or journal.

> free patents search tool < for patents in English from the European Patent Office.

Molecular oncology
Molecular oncology leverages advanced technologies to innovate cancer diagnosis and treatment through genetic and biochemical insights.

Molecular oncology investigates the genetic, epigenetic, and biochemical alterations driving cancer initiation, progression, and resistance to therapy. This domain integrates high-throughput sequencing, molecular diagnostics, and targeted therapeutics to elucidate oncogenic pathways, tumor suppressor gene inactivation, and tumor microenvironment interactions. Advances in molecular profiling, biomarker discovery, and precision medicine redefine cancer classification and treatment strategies. Our following compilation presents the latest peer-reviewed publications and patented innovations, reflecting cutting-edge research on oncogenes, signal transduction, cancer stem cells, immunomodulation, and molecular imaging techniques essential for translational oncology and clinical applications.

This is our latest selection of worldwide publications and patents in english on Molecular Oncology, between many scientific online journals, classified and focused on oncogene, tumor suppresso, signal transduction pathway, cancer genomic, epigenetics in cancer, molecular biomarker, targeted cancer therapy, cancer cell signaling, DNA mutation, microRNAs in oncology, cancer stem cell, apoptosis regulation, tumor microenvironment, cancer immunotherapy, gene expression profil, chromosomal aberration, molecular diagnostic, cancer proteomic, oncogenic pathway, cancer metastasis, molecular mechanisms of carcinogenesis, tumor heterogeneity, cancer epigenomic, oncogenic viruse, molecular targeted drug, cancer transcriptomics, DNA repair mechanism, cancer pharmacogenomic and cancer molecular patholog.

Methods for predicting and improving the efficacy of car t-cell therapy

Patent published on the 2026-05-06 in EP under Ref EP4736874 by UNIV ZUERICH [CH] (Magnani Chiara Francesca [ch], Ponzo Marianna [ch], Gaipa Giuseppe [it], Biondi Andrea [it])

Abstract: [0001] Disclosed is a treatment with a combination of inhibitors useful to improve the effectiveness of CAR T-cell therapies by inhibiting hypoxia, VEGF pathways and inflammation at the tumor microenvironment, thereby enhancing the response to CAR T-cell therapy in tumor patients. There is also disclosed a method for predicting the response to CAR T-cell therapy by determining T cell surface expression markers.[...]


Our summary: The document discusses methods to enhance CAR T-cell therapy effectiveness through inhibitors targeting hypoxia, VEGF pathways, and inflammation. It also presents a predictive method for therapy response based on T cell surface expression markers. These approaches aim to improve patient outcomes in tumor treatments.

CAR T-cell therapy, efficacy prediction, tumor microenvironment, inhibitors

Patent

A fluid processing device for processing droplets

Patent published on the 2026-05-06 in EP under Ref EP4737004 by IMEC VZW [BE] (Yurt Abdulkadir [be], Set Ying Ting [be], Moloudi Reza [be], Vandevelde Bart [be])

Abstract: [0001] The present invention relates to a fluid processing device for processing droplets. The device comprises a plate-like structure comprising a plurality of functional pixels. Each functional pixel is adapted to perform multiple operations on a droplet located on the pixel. Specifically, each pixel can selectively carry out at least two of the following processing operations: manipulating the droplet (e.g., its position), applying heat to the droplet, and subjecting the droplet to a magnetic[...]


Our summary: The invention is a fluid processing device designed for droplet manipulation. It features a plate-like structure with functional pixels that can perform multiple operations on droplets. This device integrates various microfluidic functions into a compact platform for applications in biochemical analysis and drug discovery.

microfluidics, droplet manipulation, functional pixels, biochemical analysis

Patent

A simplified molecular diagnostic workflow for detecting human immunodeficiency virus 1 (hiv-1) and hepatitis c virus (hcv)

Patent published on the 2026-04-23 in WO under Ref WO2026081001 by HIS MAJESTY THE KING IN RIGHT OF CANADA AS REPRESENTED BY THE MINI OF HEALTH [CA] (Tang David [ca], Nguyen Kelvin [ca], Michalak Karen [ca], Lacap Phil [ca], Kim John [ca], Mclaren Paul [ca])

Abstract: Described herein is a singleplex RT-LAMP-based tests using modified primer sets. Contrived whole blood samples containing HIV-1 or HCV virions were diluted in equal parts water and loaded directly into optimized RT-LAMP master mixes. To mitigate cold-chain storage dependence, RT-LAMP reactions were performed using a lyophilized master mix. The reactions were heated for, for example 30 minutes using a hand-held, battery-powered heating device for simultaneous virion lysis and amplification.[...]


Our summary: This study presents a simplified workflow for detecting HIV-1 and HCV using singleplex RT-LAMP tests with modified primers. Whole blood samples containing the viruses were diluted and directly loaded into optimized master mixes. A lyophilized master mix allowed for reactions to be performed without cold-chain storage, using a portable heating device for amplification.

RT-LAMP, HIV-1, HCV, molecular diagnostics

Patent

Combination of cancer vaccines and anti-trem2 agents for enhanced cancer immunotherapy

Patent published on the 2026-04-23 in WO under Ref WO2026085270 by UNIV TEXAS [US] (Gubin Matthew [us])

Abstract: The present disclosure generally relates to methods for treating cancer, and more specifically to combinatorial approaches using cancer vaccines together with agents targeting the TREM2 receptor to enhance anti-tumor immune responses. The invention includes methods of administering cancer vaccines in combination with anti-TREM2 agents. This approach enhances anti-tumor immunity by expanding tumor-specific T cells while reducing immunosuppressive macrophages in the tumor microenvironment. Additio[...]


Our summary: This disclosure presents methods for treating cancer using a combination of cancer vaccines and anti-TREM2 agents. The approach enhances anti-tumor immunity by increasing tumor-specific T cells and decreasing immunosuppressive macrophages. It also explores the combination of these agents with immune checkpoint inhibitors for improved therapeutic outcomes.

cancer vaccines, anti-TREM2 agents, immunotherapy, tumor microenvironment

Patent

Docking peptides and related antibody-based drug conjugates

Patent published on the 2026-04-23 in US under Ref US20260109780 by SONNET BIOTHERAPEUTICS INC [US] (Cini John K [us], Evans Nick [gb])

Abstract: [0000] Provided herein are novel docking peptides and antibody-based drug conjugates that include such docking peptides. In embodiments, the subject docking peptide allows for the controlled attachment of one or more drug moieties and a tumor targeting moiety that allows for the targeting of the drug moiety to the tumor microenvironment. [0000] In some embodiments, the antibody-based drug conjugates provided herein advantageously allows for enhanced targeted delivery of a drug payload having a c[...]


Our summary: Novel docking peptides enable controlled attachment of drug moieties for targeted delivery. Antibody-based drug conjugates enhance drug payload delivery to tumor sites. The technology allows for a controlled drug-to-antibody ratio for improved therapeutic efficacy.

docking peptides, antibody-drug conjugates, tumor targeting, drug delivery

Patent

Nk cell-derived extracellular vesicles armed with modified monoclonal antibodies to target cancer cells, and use thereof

Patent published on the 2026-04-22 in EP under Ref EP4729126 by UNIV DE MONTPELLIER UM [FR] (Villalba Gonzalez MartÍn [fr], Campos Mora Mauricio [fr])

Abstract: [0001] The invention relates to NK cell-derived extracellular vesicles, as attractive candidates for new anti-tumor therapies. Natural killer (NK) cells participate in the anti-tumor immune response by recognizing and exerting cytolytic functions on target cells. Research has focused on taking advantage of these characteristics to generate NK cell-based immunotherapies to complement treatments with therapeutic monoclonal antibodies. However, in some environments, such as the tumor microenvironme[...]


Our summary: NK cell-derived extracellular vesicles are engineered with modified monoclonal antibodies to specifically target cancer cells. This approach enhances the anti-tumor immune response while mitigating the effects of the tumor microenvironment. The versatility of this strategy allows for potential applications beyond cancer, including infections and autoimmune diseases.

extracellular vesicles, NK cells, monoclonal antibodies, cancer therapy

Patent

Glioblastoma-Derived Extracellular Vesicles Modulate &gamma;&delta; T Lymphocytes Through a MIC-Dependent Mechanism

Published on 2026-02-03 by Micaela Rosato, Paula Saibene Vlez, Alejandra Infante Cruz, Matas A. Pibuel, Federico Fuentes, Mnica Vermeulen, Juan Iturrizaga, Pablo E. Espil, Silvia Berner, Gabriela V. Salamone, Carolina C. Jancic @MDPI

Abstract: Glioblastoma (GBM) is the most aggressive and common primary brain tumor, with a median survival of less than a year after diagnosis. &amp;gamma;&amp;delta; T lymphocytes are immune cells that can migrate to tumors and induce malignant cells&amp;rsquo; apoptosis. Our previous in silico studies showed that higher &amp;gamma;&amp;delta; T-cell infiltration in GBM correlates with better patient survival, and in vitro experiments showed that GMB supernatants promote an antitumora[...]


Our summary: Glioblastoma-derived extracellular vesicles (EVs) modulate gamma delta T lymphocytes through a MIC-dependent mechanism. Increased CD69 expression, cytotoxicity, and cytokine production in T cells were observed following EV interaction. These findings offer insights for targeted immunotherapy development in glioblastoma patients.

Extracellular vesicles, Glioblastoma, Gamma delta T lymphocytes, Immunotherapy

Publication

Dynamic microRNA Signatures as Biomarkers for Cardiac Ischemia and Remodeling

Published on 2026-02-03 by Macarena Rodrguez-Serrano, Elena Martn-Garca, Patricia Alonso-Andrs, Elisa Conde-Moreno, Hctor Pian, Javier del Moral-Salmoral, Nunzio Alcharani, Miriam Menacho-Romn, Lorena Crespo-Toro, Miren Edurne Ramos-Muoz, Carlos Zaragoza, Luis Miguel Rincn, Mara G. Barderas, Mara Laura Garca-Bermejo @MDPI

Abstract: Myocardial infarction (MI) triggers complex pathological processes, including inflammation, hypoxia, and fibrotic remodeling. MicroRNAs (miRNAs) have emerged as promising biomarkers for cardiovascular injury; however, their expression dynamics along processes remain underexplored. We used an in vivo rat model of permanent coronary occlusion to study the molecular alterations associated with MI and its resolution in a temporal mode, including five experimental groups with five animals in each: sh[...]


Our summary: This study investigates the dynamic expression of microRNAs as biomarkers for cardiac ischemia following myocardial infarction. Using a rat model, it identifies specific miRNAs that correlate with the progression and resolution of myocardial injury over time. The findings suggest that these miRNA signatures can serve as noninvasive indicators of cardiac stress and potential therapeutic targets.

microRNA, cardiac ischemia, biomarkers, myocardial infarction

Publication

Topics covered: Molecular Oncology, genetic alterations, epigenetic alterations, biochemical alterations, high-throughput sequencing, molecular diagnostics, targeted therapeutics, oncogenic pathways, tumor suppressor genes, tumor microenvironment, biomarker discovery, precision medicine, cancer classification, immunomodulation, molecular imaging, translational oncology, clinical applications, peer-reviewed publications, patented innovations ISO 15189, ISO 9001, ISO/IEC 17025, CLSI guidelines, and ASTM E2876..

Historical Context

1965
1970
1980
1980
1990
1960
1969
1976-05-28
1980
1990

(if date is unknown or not relevant, e.g. "fluid mechanics", a rounded estimation of its notable emergence is provided)

Full size images and downloads are only available, 100% free, for registered members.

> Login <